nach oben

Current Dermatology Reports

Erschienen in:

02.09.2016 | Wound Care and Healing (A Friedman, Section Editor)

Updates on Keloidal Wound Healing

verfasst von: Andrea D. Maderal, Brian Berman

Erschienen in: Current Dermatology Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Keloids represent an abnormal response to wound healing. Despite significant study into this area, the pathogenesis overall remains unclear. And though numerous therapies have been evaluated, many of these treatments have only been supported by weak evidence, and cosmetic results are often disappointing.

Recent Findings

With regard to pathogenesis, there is a genetic predisposition in certain populations to keloid development, and the role of epithelial and endothelial to mesenchymal transformation is being found to be important. Therapies that target this transition, such as mesenchymal stem cells, are being studied. Proteins that alter production of TGF-beta, a cytokine involved in the development of keloids, are being identified and represent potential upstream targets. So too are therapies targeting TGF-beta directly being studied. Finally, several therapies, new and old, have been evaluated in clinical trials.

Summary

Insights into the pathogenesis of keloids have led to development of promising therapies for keloids.

Zhu F, Wu B, Li P, Wang J, Tang H, Liu Y, et al. Association study confirmed susceptibility loci with keloid in Chinese Han population. PLoS One. 2013;8:e62377.CrossRefPubMedPubMedCentral

2.•

Ogawa R, Watanabe A, Than Naing B, Sasaki M, Fujita A, Akaishi S, et al. Associations between keloid severity and single-nucleotide polymorphisms: importance of rs8032158 as a biomarker of keloid severity. J Invest Dermatol. 2014;134:2041–3 .This study identified a new SNP, rs8032158, encoding a portion of neuronal precursor cell-expressed developmentally downregulated 4 (NEDD4), as not only a risk factor for keloid development, but also severity CrossRefPubMed

3.•

Velez Edwards DR, Tsosie KS, Williams SM, Edwards TL, Russell SB. Admixture mapping identifies a locus at 15q21.2-22.3 associated with keloid formation in African Americans. Human Genet. 2014;133:1513–23 .This study demonstrated an association between mutations in myosin-encoding genes and development of keloids in African Americans CrossRef

4.•

Tosa M, Watanabe A, Ghazizadeh M. IL-6 polymorphism and susceptibility to keloid formation in a Japanese population. J Invest Dermatol. 2016;136:1069–72 .This study found mutation in IL-6 gene to be associated with keloids in a Japanese cohort CrossRefPubMed

5.•

Yan L, Cao R, Wang L, Liu Y, Pan B, Yin Y, et al. Epithelial-mesenchymal transition in keloid tissues and TGF-b1-induced hair follicle outer root sheath keratinocytes. Wound Repair Regen. 2015;23:601–10 .This study evaluated the role of epithelial-mesenchymal transition in keloid pathogenesis. The authors found loss of epithelial markers and gain of mesenchymal markers in keloid epidermis and dermis, as well as enhanced TGF-beta-1 expression CrossRefPubMed

Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 2009;1:303–14.CrossRefPubMedPubMedCentral

Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed

Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.CrossRefPubMedPubMedCentral

9.•

Lee WJ, Park JH, Shin JU, Noh H, Lew DH, Yang WI, et al. Endothelial-to-mesenchymal transition induced by Wnt 3a in keloid pathogenesis. Wound Repair Regen. 2015;23:435–42 .This study evaluated the role of endothelial-to-mesenchymal transition in keloid pathogenesis. The authors found keloidal fibroblasts demonstrated upregulation of endothelial markers, suggesting an endothelial origin, as well as upregulation of Wnt-3a, thought to be pathogenic in this transition CrossRefPubMed

10.

Li J, Bertram JF. Review: Endothelial-myofibroblast transition, a new player in diabetic renal fibrosis. Nephrology (Carlton). 2010;15:507–12.CrossRef

11.

Joly AL, Wettstein G, Mignot G, Ghiringhelli F, Garrido C. Dual role of heat shock proteins as regulators of apoptosis and innate immunity. J Innate Immun. 2010;2:238–47.CrossRefPubMed

12.

Taiyab A, Rao CM. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion. Biochim Biophys Acta. 2011;1813:213–21.CrossRefPubMed

13.

Li J, Sun X, Wang Z, Chen L, Li D, Zhou J, et al. Regulation of vascular endothelial cell polarization and migration by Hsp70/Hsp90-organizing protein. PLoS One. 2012;7:e36389.CrossRefPubMedPubMedCentral

14.

Rappa F, Farina F, Zummo G, David S, Campanella C, Carini F, et al. HSP-molecular chaperones in cancer biogenesis and tumor therapy: an overview. Anticancer Res. 2012;32:5139–50.PubMed

.15••

Yun IS, Lee MH, Rah DK, Lew DH, Park JC, Lee WJ. Heat shock protein 90 inhibitor (17-AAG) induces apoptosis and decreases cell migration / motility of keloid fibroblasts. Plast Reconstr Surg. 2015;136:44e–53e .This study evaluated the role of HSP-90, a cellular chaperone for TGF-beta receptors I and II, in keloidal tissues. The authors found that inhibition of HSP-90 led to decreased proliferation and increased apoptosis of keloidal fibroblasts CrossRefPubMed

16.

Wrighton KH, Lin X, Feng XH. Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci U S A. 2008;105:9244–9.CrossRefPubMedPubMedCentral

17.•

Lee WJ, Lee JH, Ahn HM, Song SY, Kim YO, Lew DH, et al. Heat shock protein 90 inhibitor decreases collagen synthesis of keloid fibroblasts and attenuates the extracellular matrix on the keloid spheroid model. Plast Reconstr Surg. 2015;136:328e–37e .This study demonstrated that inhibition of HSP-90 resulted in decreased collagen synthesis by keloidal fibroblasts CrossRefPubMedPubMedCentral

18.

Jumper N, Paus R, Bayat A. An innovative approach to dissecting keloid disease leading to identification of the retinoic acid pathways as a potential therapeutic target. Plast Reconstr Surg Glob Open. 2016;4:e601.CrossRefPubMedPubMedCentral

19.••

Jumper N, Hodgkinson T, Arscott G, Har-Shai Y, Paus R, Bayat A. The aldo-keto reductase AKR1B10 is up-regulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease. J Invest Dermatol. 2016. doi:10.1016/j.jid.2016.03.022 .This study evaluated the role of retinoic acid on keloid pathogenesis. The authors found upregulation of AKR1B10, a key enzyme in metabolism of retinoic acid, in keloid epidermis, leading to reduced retinoic acid levels and increased TGF-beta and collagen PubMed

20.

Kwon SY, Park SH, Park K. Comparative effect of topical silicone gel and topical tretinoin cream for the prevention of hypertrophic scar and keloid formation and the improvement of scars. J Eur Acad Dermatol Venereol. 2014;28:1025–33.CrossRefPubMed

21.

Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol. 1988;14:1275–6.CrossRefPubMed

22.

Zang Y, Wang T, Xie W, Wang-Fischer YL, Getty L, Han J, et al. Regulation of acetyl CoA carboxylase and carnitine palmitoyl transferase-1 in rat adipocytes. Obes Res. 2005;13:1530–9.CrossRefPubMed

23.

Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao DF, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 2008;283:3418–23.CrossRefPubMed

24.

Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K, et al. Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10. Chem Biol Interact. 2015;230:30–9.CrossRefPubMed

25.

O’Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol. 1997;29:63–78.CrossRefPubMed

26.

Smith P, Mosiello G, Deluca L, Ko F, et al. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res. 1999;82:319–23.CrossRefPubMed

27.

Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108:985–1002.PubMed

28.

Occleston NL, O’Kane S, Laverty HG, Cooper M, et al. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011;19(Suppl 1):s38–48.CrossRefPubMed

29.

Young L. Trial of Juvista (Avotermin) following removal of ear lobe keloid scars. Retrieved June 11, 2016, from https://clinicaltrials.gov/ct2/show/NCT00469235.

30.

Young V. Exploratory study of the efficacy and safety of Juvista 250 ng when administered following excision of ear lobe keloids. Retrieved June 11, 2016, from https://clinicaltrials.gov/ct2/show/NCT00836147.

31.

Young V. Safety of Juvista when administered following excision of ear lobe keloids (RN1001–0093). Retrieved June 11, 2016, from https://clinicaltrials.gov/ct2/show/NCT00710333.)

32.•

Mun JH, Kim YM, Kim BS, Kim JH, Kim MB, Ko HC. Simvastatin inhibits transforming growth factor-b1-induced expression of type I collagen, CTGF, and a-SMA in keloid fibroblasts. Wound Repair Regen. 2014;22:125–33 .This study investigated the role of statins in keloid pathogenesis, and found that administration to keloidal fibroblasts resulted in decreased production of pro-fibrotic proteins and cytokines CrossRefPubMed

33.

Munford RS. Statins and the acute-phase response. N Engl J Med. 2011;344:2016–8.CrossRef

34.

Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006;6:358–70.CrossRefPubMed

35.

Burke JP, Watson RW, Murphy M, Docherty NG, Coffey JC, O’Connell PR. Simvastatin impairs smad-3 phosphorylation and modulates transforming growth factor beta1-mediated activation of intestinal fibroblasts. Br J Surg. 2009;96:541–51.CrossRefPubMed

36.

Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317–24.CrossRefPubMedPubMedCentral

37.

Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am J Respir Cell Mol Biol. 2005;32:290–300.CrossRefPubMed

38.

Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins. Br J Pharmacol. 2001;133:1172–80.CrossRefPubMedPubMedCentral

39.

Ikeda K, Torigoe T, Matsumoto Y, Fujita T, Sato N, Yotsuyanagi T. Resveratrol inhibits fibrogenesis and induces apoptosis in keloid fibroblasts. Wound Repair Regen. 2013;21:616–23.CrossRefPubMed

40.

Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–6.CrossRefPubMed

41.

Godichaud S, Krisa S, Couronne B, Dubuisson L, Merillon JM, Desmouliere A, et al. Deactivation of cultured human liver myofibroblasts by trans-resveratrol, a grapevine-derived polyphenol. Hepatology. 2000;31:922–31.CrossRefPubMed

42.

Chavez E, Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Vergara P, et al. Resveratrol prevents fibrosis, NF-kappaB activation and TGF-beta increases induced by chronic CCI4 treatment in rats. J Appl Toxicol. 2008;28:35–43.CrossRefPubMed

43.•

Grant C, Chudakova DA, Itinteang T, Chibnail AM, Brasch HD, David PF, et al. Expression of embryonic stem cell markers in keloid-associated lymphoid tissue. J Clin Pathol. 2016 Mar 30. doi:10.1136/jclinpath-2015-203483 .The authors identified a stem cell-like population within keloids

44.

Moon JH, Kwak SS, Park G, Jung HY, Yoon BS, Park J, et al. Isolation and characterization of multipotent human keloid-derived mesenchymal-like stem cells. Stem Cells Dev. 2008;17:713–24.CrossRefPubMed

45.••

Fang F, Huang RL, Zheng Y, Liu M, Huo R. Bone marrow derived mesenchymal stem cells inhibit the proliferative and profibrotic phenotype of hypertrophic scar fibroblasts and keloid fibroblasts through paracrine signaling. J Dermatol Sci. 2016 Mar 4. doi:10.1016/j.jdermsci.2016.03.003 .The authors studied the role of bone marrow-derived mesenchymal stem cell-conditioned medium on keloidal fibroblasts and found decreased expression of pro-fibrotic cytokines and decreased extracellular matrix synthesis

46.

Jackson WM, Nesti LJ, Tuan RS. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res Ther. 2012;3:20.CrossRefPubMedPubMedCentral

47.

Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int. 2014;2014:340257.CrossRefPubMedPubMedCentral

48.

Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10:459–66.PubMed

49.

Zhang Z, Lin H, Shi M, Xu R, Gu J, Lv J, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27:112–20.CrossRefPubMed

50.

Lee MJ, Jung J, Na KH, Moon JS, Lee HJ, Kim JH, et al. Anti-fibrotic effect of chorionic plate-derived mesenchymal stem cells isolated from human placenta in a rat model of CCI(4)-injured liver: potential application to the treatment of hepatic diseases. J Cell Biochem. 2010;111:1453–63.CrossRefPubMed

51.

Cherubino M, Rubin JP, Miljkovic N, Kelmendi-Doko A, Marra KG. Adipose-derived stem cells for wound healing applications. Ann Plast Surg. 2011;66:210–5.CrossRefPubMed

52.••

Fong CY, Biswas A, Subramanian A, Srinivasan A, Choolani M, Bongso A. Human keloid cell characterization and inhibition of growth with human Wharton’s jelly stem cell extracts. J Cell Biochem. 2014;115:826–38 .This study evaluated the response of keloidal fibroblasts in vitro to administration of human Wharton’s jelly mesenchymal stem cells. They found linear decreases in cell proliferation and migration CrossRefPubMed

53.

Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids. J Drugs Dermatol. 2011;10:468–80.PubMed

54.

Berman B, Garikaparthi S, Smith E, Newburger J. A novel hydrogel scaffold for the prevention or reduction of the recurrence of keloid scars postsurgical excision. J Am Acad Dermatol. 2013;69:828–30.CrossRefPubMed

55.

Ogawa R, Okai K, Tokumara F, Mori K, Ohmori Y, Huang C, et al. The relationship between skin stretching/contraction and pathologic scarring: the important role of mechanical forces in keloid generation. Wound Repair Regen. 2012;20:149–57.CrossRefPubMed

56.•

Longaker MT, Rohrich RJ, Greenberg L, Furnas H, Wald R, Bansal V, et al. A randomized controlled trial of the embrace advanced scar therapy device to reduce incisional scar formation. Plast Reconstr Surg. 2014;134:536–46 .This randomized controlled trial found improved clinical scar outcomes after treatment of patients with a tension-offloading device, Embrace Advanced Scar Therapy device, post-abdominoplasty as compared to controls CrossRefPubMedPubMedCentral

57.

Christensen E, Warloe T, Kroon S, Funk J, Helsing P, Soler AM, et al. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol. 2010;24:505–12.CrossRefPubMed

58.

Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part I: photochemistry and photobiology. J Eur Acad Dermatol Venereol. 2007;21:293–302.CrossRefPubMed

59.

Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. Internal Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol. 2007;56:125–43.CrossRefPubMed

60.

Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky KE. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B. 2001;62:140–5.CrossRefPubMed

61.

Ud-Din S, Thomas G, Morris J, Bayat A. Photodynamic therapy: an innovative approach to the treatment of keloid disease evaluated using subjective and objective non-invasive tools. Arch Dermatol Res. 2013;305:205–14.CrossRefPubMed

62.•

Tanaydin V, Beugels J, Piatkowski A, Colla C, van den Kerckhove E, Hugenholtz GC, et al. Efficacy of custom-made pressure clips for ear keloid treatment after surgical excision. J Plast Reconstr Aesthet Surg. 2016;69:115–21 .This study evaluated custom-molded earclips as adjuvant therapy post-excision of earlobe keloids and found recurrence rate of 29.5% CrossRefPubMed

63.

Hayashi T, Furukawa H, Oyama A, Funayama E, Saito A, Murao N, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg. 2012;38:893–7.CrossRefPubMed

64.

Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol. 2009;34:219–23.CrossRefPubMed

65.

Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg. 2004;30:54–6.PubMed

66.••

Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. Acta Derm Venereol. 2015;95:778–82 .This systematic review found that combination therapy of 5-fluorouracil with triamcinolone was superior to triamcinolone or 5-fluorouracil alone PubMed

.67••

Shin JY, Kim JS. Could 5-fluorouracil or triamcinolone be an effective treatment option for keloid after surgical excision? A meta-analysis. J Oral Maxillofac Surg. 2016;74:1055–60 .This meta-analysis found lower recurrence rates post-keloid excision in subjects treated with 5-fluorouracil than triamcinolone CrossRefPubMed

68.

Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermtol Venereol Leprol. 2008;74:343–8.CrossRef

69.•

Danielsen PL, Rea SM, Wood FM, Fear MW, Viola HM, Hool LC, et al. Verapamil is less effective than triamcinolone for prevention of keloid scar recurrence after excision in a randomized controlled trial. Acta Derm Venereol. 2016 Feb 25. doi:10.2340/00015555-2384 .This study was a double-blind, randomized controlled trial with a split-scar design that compared intralesional verapamil to intralesional triamcinolone. The authors demonstrated a higher recurrence with verapamil as compared to triamcinolone

70.

Keeling BH, Whitsitt J, Liu A, Dunnick CA. Keloid removal by shave excision with adjuvant external beam radiation therapy. Dermatol Surg. 2015;41:989–92.CrossRefPubMed

71.••

van Leewen MC, Stokmans SC, Bulstra AE, Meijer OW, Heymans MW, Ket JC, et al. Surgical excision with adjuvant irradiation for treatment of keloid scars: a systematic review. Plast Reconstr Surg Glob Open. 2015;3 :–e440.This systematic review evaluated the role of radiation therapy as adjuvant treatment post-excision of keloids. The authors found that high-dose brachytherapy had lower recurrence rates as compared to low-dose brachytherapy and external radiation, and that shorter intervals between excision and radiation resulted in lower recurrence rates

Titel: Updates on Keloidal Wound Healing
verfasst von: Andrea D. Maderal
Brian Berman
Publikationsdatum: 02.09.2016
Verlag: Springer US
Erschienen in: Current Dermatology Reports / Ausgabe 4/2016
Elektronische ISSN: 2162-4933
DOI: https://doi.org/10.1007/s13671-016-0155-4

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Updates on Keloidal Wound Healing

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Wound Dressings: A Comprehensive Review

Leg Ulcers in Dermatology

Dermatology in the Disruptive Economy

Human as the Ultimate Wound Healing Model: Strategies for Studies Investigating the Dermal Lipidome

Invited Commentary on Teledermatology Education: the Evidence, the Tools, and the Potential ECHO

Nanomaterials for Wound Healing

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie